Effects of sitagliptin on gastric emptying of, and the glycaemic and blood pressure responses to, a carbohydrate meal in type 2 diabetes.
Aged
Blood Glucose
Blood Pressure
Cross-Over Studies
Diabetes Mellitus, Type 2
/ drug therapy
Dietary Carbohydrates
/ administration & dosage
Double-Blind Method
Female
Gastric Emptying
/ drug effects
Humans
Hypoglycemic Agents
/ therapeutic use
Male
Postprandial Period
Sitagliptin Phosphate
/ therapeutic use
DPP-4 inhibition
blood pressure
glycaemia
postprandial hypotension
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
09
07
2019
revised:
13
08
2019
accepted:
25
08
2019
pubmed:
31
8
2019
medline:
21
5
2021
entrez:
31
8
2019
Statut:
ppublish
Résumé
To determine the effects of the dipeptidyl peptidase-4 inhibitor, sitagliptin, on gastric emptying (GE) of a high-carbohydrate meal and associated glycaemic and blood pressure (BP) responses in type 2 diabetes mellitus (T2DM). Fourteen patients with T2DM (nine men, five women; age 67.8 ± 1.5 years; body mass index 31.2 ± 0.9 kg/m Sitagliptin reduced postprandial plasma glucose (P < .005) without affecting GE (P = .88). The magnitude of the glucose-lowering effect (change in incremental area under the curve In T2DM, while sitagliptin has no effect on either GE or postprandial BP, its ability to lower postprandial glucose are dependent on the basal rate of GE.
Substances chimiques
Blood Glucose
0
Dietary Carbohydrates
0
Hypoglycemic Agents
0
Sitagliptin Phosphate
TS63EW8X6F
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-58Subventions
Organisme : Royal Adelaide Hospital Research Foundation
Pays : International
Organisme : University of Adelaide Beacon Research Fellowship
Pays : International
Organisme : Royal Adelaide Hospital Florey Fellowship
Pays : International
Organisme : National Health and Medical Research Council (NHMRC)
Pays : International
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Phillips LK, Deane AM, Jones KL, Rayner CK, Horowitz M. Gastric emptying and glycaemia in health and diabetes mellitus. 2015;11:112-128.
Jones KL, Horowitz M, Carney BI, Wishart JM, Guha S, Green L. Gastric emptying in "early" noninsulin-dependent diabetes mellitus relationship to oral glucose tolerance and appetite. J Nucl Med. 1996;37:1643-1648.
Wu T, Little TJ, Bound MJ, et al. A protein preload enhances the glucose-lowering efficacy of vildagliptin in type 2 diabetes. Diabetes Care. 2016;39:511-517.
Watson LE, Xie C, Wang X, et al. Gastric emptying in patients with well-controlled type 2 diabetes compared to non-diabetic young and older controls. J Clin Endocrinol Metab. 2019;104:3311-3319.
Little TJ, Pilichiewicz AN, Russo A, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab. 2006;91:1916-1923.
Deane AM, Nguyen NQ, Stevens JE, et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab. 2010;95:215-221.
Umapathysivam MM, Lee MY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63:785-790.
Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60:1561-1565.
Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38:1263-1273.
Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151:123-129.
Nonaka T, Sekino Y, Iida H, et al. Early effect of single-dose Sitagliptin administration on gastric emptying: crossover study using the (13)C breath test. J Neurogastroenterol Motil. 2013;19:227-232.
Nauck MA, Kind J, Kothe LD, et al. Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition with vildagliptin in healthy subjects and patients with type 2 diabetes using exendin [9-39] as a GLP-1 receptor antagonist. Diabetes. 2016;65:2440-2447.
Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study. Aliment Pharmacol Ther. 2012;36:379-390.
Wu T, Bound MJ, Zhao BR, et al. Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes. Diabetes Care. 2013;36:1913-1918.
Vella A, Bock G, Giesler PD, et al. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol (Oxf). 2008;69:737-744.
Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007;56:1475-1480.
Aulinger BA, Bedorf A, Kutscherauer G, et al. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes. 2014;63:1079-1092.
Wu T, Zhang X, Trahair LG, et al. Small intestinal glucose delivery affects the lowering of blood glucose by acute vildagliptin in type 2 diabetes. J Clin Endocrinol Metab. 2016;101:4769-4778.
Pilichiewicz AN, Chaikomin R, Brennan IM, et al. Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am J Physiol Endocrinol Metab. 2007;293:E743-E753.
Ma J, Pilichiewicz AN, Feinle-Bisset C, et al. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes. Diabet Med. 2012;29:604-608.
Trahair LG, Horowitz M, Jones KL. Postprandial hypotension: a systematic review. J Am Med Dir Assoc. 2014;15:394-409.
Jones KL, Tonkin A, Horowitz M, et al. Rate of gastric emptying is a determinant of postprandial hypotension in non-insulin-dependent diabetes mellitus. Clin Sci (Lond). 1998;94:65-70.
Wu T, Trahair LG, Bound MJ, et al. Effects of sitagliptin on blood pressure and heart rate in response to intraduodenal glucose infusion in patients with Type 2 diabetes: a potential role for glucose-dependent insulinotropic polypeptide? Diabet Med. 2014;32:595-600.
Trahair LG, Horowitz M, Stevens JE, et al. Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes. Diabetologia. 2015;58:1769-1778.
Yonenaga A, Ota H, Honda M, et al. Marked improvement of elderly postprandial hypotension by dipeptidyl peptidase IV inhibitor. Geriatr Gerontol Int. 2013;13:227-229.
Saito Y, Ishikawa J, Harada K. Postprandial and orthostatic hypotension treated by Sitagliptin in a patient with dementia with Lewy bodies. Am J Case Rep. 2016;17:887-893.
Hojberg PV, Vilsboll T, Rabol R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52:199-207.
Witte AB, Gryback P, Holst JJ, et al. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man. Regul Pept. 2009;158:57-62.
Trahair LG, Horowitz M, Hausken T, Feinle-Bisset C, Rayner CK, Jones KL. Effects of exogenous glucagon-like peptide-1 on the blood pressure, heart rate, mesenteric blood flow, and glycemic responses to intraduodenal glucose in healthy older subjects. J Clin Endocrinol Metab. 2014;99:E2628-E2634.
Smits MM, Tonneijck L, Muskiet MH, et al. The effects of GLP-1 based therapies on postprandial haemodynamics: two randomised, placebo-controlled trials in overweight type 2 diabetes patients. Diabetes Res Clin Pract. 2017;124:1-10.
Jones KL, Rigda RS, Buttfield MDM, et al. Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes. Diabetes Obes Metab. 2019;21:1158-1167.